Funding for this research was provided by:
National Institute on Drug Abuse (R01DA021579)
Received: 27 August 2018
Accepted: 15 November 2019
First Online: 2 December 2019
Ethics approval and consent to participate
: The parent study was approved by the Friends Research Institute’s Institutional Review Board, the Maryland Department of Public Safety and Correctional Services Research Committee, and the Federal Office for Human Research Protections.
: Not applicable.
: This study was supported by an unrestricted, unsolicited investigator initiated request from Reckitt Benckiser Pharmaceuticals, Inc. (provided study drug only) who had no role in study design; collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication. The authors alone are responsible for the content and writing of this manuscript. Dr. Blue reports no conflicts of interest. Drs. Gordon and Vocci are currently receiving free study drugs from Alkermes for an unrelated project. Dr. Schwartz provides consultation to Verily Life Sciences. Ms. Couvillion reports no competing interests. Dr. Vocci reports personal fees and other from Braeburn Pharmaceuticals; personal fees and other from Pinney Associates; personal fees and other from Indivior, personal fees and other from Demerx; personal fees from Alkermes; personal fees and other from Insys Pharmaceuticals; and stock ownership from Intratab Labs, Inc. Drs. Fitzgerald and O’Grady report no competing interests.